PAREXEL Opens Shenyang Office to Support Business Growth in Asia
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Shenyang, China. This location will support growing client demand for a broad range of clinical development capabilities in the country and throughout the Asia Pacific region. The office further expands PAREXEL’s presence in China which includes locations in Beijing, Chengdu, Guangzhou, Shanghai and Hong Kong. PAREXEL now has 22 offices throughout important biopharmaceutical centers in the Asia Pacific region, which in addition to China, includes a presence in Australia, Japan, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
“Given the globalization of clinical trials today and the continuing shift of drug development activity from West to East, China has become an important strategic destination for PAREXEL’s clients and business,” said Mark Goldberg, PAREXEL’s President and COO. “With the opening of the Shenyang operation hub in China, PAREXEL commits to continuing to expand its service scope and local expertise. The office also further reinforces our social investment in the region through a collaboration with Shenyang Pharmaceutical University to train graduates on clinical trial conduct, data management and pharmacovigilance knowledge.”
The Shenyang office will also enable the Company to bring Perceptive eClinical technology solutions to the Asia Pacific market. Built on the leading-edge PAREXEL MyTrials™ platform and combined with PAREXEL’s extensive medical and clinical expertise, clinical trial sponsors are able to more efficiently manage the clinical development process from study design to data collection and ultimately, to regulatory submission.
As part of the initiative, PAREXEL Academy will offer graduates and alumni of Shenyang Pharmaceutical University’s School of Life Science and Biopharmaceuticals opportunities to work alongside PAREXEL staff who are involved in regional and global clinical studies. This offering is in addition to the abundant full-time PAREXEL career opportunities already available to the same graduates and alumni.
“We are pleased to have the opportunity to collaborate with PAREXEL, one of the CRO industry leaders,” said Professor Jing-Yu Yang, Dean of Shenyang Pharmaceutical University. “The collaboration will not only provide our Clinical Pharmacy students with the opportunity to learn about new drug development, but it will also create a foundation for research and cultivation of the next generation of talent.”
A ceremony to mark the official opening of PAREXEL’s Shenyang operations will take place on Thursday, May 16.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
